 TORRANCE, Calif., May 26, 2021 PRNewswire -- Emmaus Life Sciences, Inc. OTC: EMMA, a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that its application for Marketing Authorization MA for Endari in the Kingdom of Saudi Arabia has been accepted by the Saudi Food and Drug Authority SFDA. 